Invesaro

Invesaro publishes investment theses and settles them against the market in public: with a date, a basket of companies and a verdict.

Investment thesis

Radiopharmaceuticals cannot be stockpiled: the cancer isotope boom pays the networks, not the molecules

LivePublished August 20, 2026180-day horizonsupply and demand
Watch this thesis

In short

  1. What is happening
    Radioligand therapy moves into earlier cancer lines
  2. Why it matters
    Every radioligand dose decays within days, so scale depends on licensed hot cells near patients, and that is where the profit pool quietly sits.
  3. Who benefits
    Eckert & Ziegler SE, Ion Beam Applications SA, Lantheus Holdings, Telix Pharmaceuticals
  4. What must hold
    Assumptions are statements that must stay true for the thesis to make sense.
    Assumptions: 5. See the assumptions
  5. When is the verdict
    The horizon is the time we give a thesis. That many days after publication we settle it: we compare the basket of companies with the market benchmark and give a verdict.
    February 16, 2027, 180 days after publication
  6. Our score at publication
    A score from 0 to 100 given on the day of publication, before the market has verified anything. On the results page we check in public whether higher-scored theses do better.
    57 out of 100
Basket return
-4.0%
equal weight, since publication
The market over the same window
-1.6%
benchmark for this basket
Edge over the market
-2.4%
in percentage points

Companies in the basket

EUZEckert & Ziegler SEIBABIon Beam Applications SALNTHLantheus HoldingsTLXTelix Pharmaceuticals

The argument

Radioligand therapy has stopped being a niche of nuclear medicine and become a funded priority of the largest balance sheets in pharma. Novartis pushed Pluvicto into earlier lines of prostate cancer, and between 2023 and 2025 Eli Lilly, Bristol Myers Squibb, AstraZeneca and Novartis each bought a radiopharmaceutical developer outright. The pipeline that follows is not a handful of trials but dozens of programmes aimed at prostate, neuroendocrine, kidney and lung tumours, all of which converge on the same physical infrastructure.

Here is the part the market keeps mispricing. A radiopharmaceutical is the only drug class where inventory is physically impossible. Lutetium-177 loses half its activity in 6.6 days, actinium-225 in about 10 days, gallium-68 in 68 minutes and fluorine-18 in under two hours. There is no safety stock, no warehouse, no rebuilding of a supply buffer after a bad quarter. The dose is made to order for a named patient on a named day, and if the courier is late the product is simply weaker than the prescription. Every other pharmaceutical bottleneck in the last decade, from GLP-1 pens to sterile vials, could in principle be solved by running the line longer. This one cannot.

What this thesis rests on

Each one is a statement that has to be true. We go back to every live thesis on a schedule and check these against public sources, so each leg carries either what we found or the date we look next.

Archive: reviews of this thesis are paused. Last review September 18, 2026.

  1. Eckert & Ziegler's Medical segment revenue grows at least 10% year over year in each of the two quarterly reports published after this thesis.

    financial · Open

    Checked September 18, 2026, nothing published either way

  2. Lantheus's radiodiagnostics revenue falls by no more than 10% year over year in each of the two quarterly reports published after this thesis.

    financial · Open

    Checked September 18, 2026, nothing published either way

  3. CMS retains separate payment for diagnostic radiopharmaceuticals above the per day cost threshold in the CY2027 Hospital Outpatient Prospective Payment System rulemaking.

    regulatory · Open

    Checked September 18, 2026, nothing published either way

  4. At least one new GMP radiopharmaceutical production site or hot cell expansion in the US or EU is announced by Eckert & Ziegler, Telix or Lantheus before 28 February 2027.

    operational · Open

    Checked September 18, 2026, nothing published either way

  5. Telix keeps FDA marketing authorisation for Illuccix and discloses no supply interruption of its PSMA imaging products during the horizon.

    competitive · Supported

    A source confirms this · September 4, 2026

    Telix H1 2026 results, released 20 Aug 2026, state Illuccix is commercially available in 22 countries including the U.S., and Precision Medicine revenue rose 27% year over year on Illuccix and Gozellix sales volume growth and market share gains. The release discloses no supply interruption of the PSMA imaging products.

    See the source
Show the causal chain step by step
  1. Radioligand therapy moves into earlier cancer lines
  2. Medicare pays separately for costly PET tracers
  3. Half-lives of days or hours make inventory impossible
  4. Each therapy patient needs PET selection and follow-up
  5. Growth needs licensed hot cells near the patient
  6. Isotope supply and network density become the constraint
  7. Isotope suppliers, accelerator makers, tracer networks

This thesis, over time

What has happened since publication. Every entry is computed as of its own date, from price history.

October 4, 2026

Day 45 of 180: basket -4.0%

The first quarter of the horizon is behind this thesis. The equal-weight basket stands at -4.0% since publication day. The benchmark (S&P 500) returned -1.6% over the same window, so the basket trails its market by 2.4 percentage points. The strongest contributor is LNTH (+0.3%), the weakest is EUZ (-11.1%). 135 days remain until the verdict.

September 18, 2026

Review on day 29: nothing moved

We went back to this thesis on day 29 of 180 and checked each of its 5 assumptions against public sources. No news either way: 5. The equal-weight basket stands at -4.0% since publication day. The benchmark (.INX) returned -1.6% over the same window, so the basket trails its market by 2.4 percentage points. 151 days remain until the verdict.

September 4, 2026

Review: 1 of 5 assumptions confirmed

We went back to this thesis on day 15 of 180 and checked each of its 5 assumptions against public sources. Confirmed by the sources: 1. No news either way: 4. The equal-weight basket stands at -2.4% since publication day. The benchmark (.INX) returned +0.5% over the same window, so the basket trails its market by 2.9 percentage points. 165 days remain until the verdict.

New theses straight to your inbox

Subscribe and we will send you every new thesis and every verdict. No spam, one-click unsubscribe.

This is analysis, not investment advice and not a recommendation to buy or sell anything. We publish it and track it in public, mistakes included. Any decision is yours and yours alone.